Metabolic-associated fatty liver disease (MAFLD) has emerged as a leading cause of progressive liver disease, even leading to a risk of hepatocellular carcinoma (HCC). Animal models that mimic the key etiological and histological features of the liver in the context of metabolic dysfunction represent the basis of preclinical research in MAFLD. The aim of work from researchers at Guangdong Pharmaceutical University was to develop a diet-induced murine model of MAFLD progressing to fibrosis and HCC.
The pathogenesis of eosinophilic gastroenteritis (EGE), a chronic inflammatory disease characterized by eosinophil infiltration in the gastrointestinal tract, is still not well understood.
Researchers from Yonsei University reported their findings from a study that aimed to investigate the mechanisms underlying aberrant actin remodeling in inflammatory bowel disease (IBD). Revision of public gene expression datasets of rectum biopsy samples from patients with IBD identified a subset of patients that exhibited substantially higher levels of tripartite motif-containing protein 40 (TRIM40), a gene that is epigenetically silenced under healthy conditions.
Bridge Biotherapeutics Inc.’s small-molecule Pellino-1 inhibitor, BBT-401, failed to meet the primary efficacy endpoint in a phase II trial in ulcerative colitis (UC). The phase II mid-to-high dose cohort study included 38 patients with active UC enrolled at 37 clinical sites across the U.S., New Zealand, South Korea, Poland and Ukraine.
Carephar Pharmaceutical Co. Ltd. obtained marketing approval for keverprazan (KFP-H008) from China’s NMPA for use in duodenal ulcer and reflux esophagitis treatments, allowing it to tap an increasingly competitive market.
One of the most important transformations in the pharmaceutical industry over the next decade is the ability to modify genes or expression and go after any target, Cargene Biopharma Inc. CEO Kathy He told BioWorld, explaining that small molecules and large molecules can only go after 15% of the known targets. But the technology platform of short-interfering RNA (siRNA) opens a huge opportunity to make those inaccessible targets available, she said.
One of the most important transformations in the pharmaceutical industry over the next decade is the ability to modify genes or expression and go after any target, Cargene Biopharma Inc. CEO Kathy He told BioWorld, explaining that small molecules and large molecules can only go after 15% of the known targets. But the technology platform of short-interfering RNA (siRNA) opens a huge opportunity to make those inaccessible targets available, she said.
When oxygen levels of the intestine increase, the appropriate hypoxic conditions for intestinal microbiota are lost. This state may be caused by immune-mediated malfunction of the intestinal epithelium. By controlling oxygen levels, the imbalance in the intestinal microbiome (dysbiosis) can be reduced.
Boston Immune Technologies and Therapeutics Inc. (BITT) has announced progress using its Domab platform. Two Domab CD40 antagonists, BITT-CD4D11 and BITT-CD4F10, have completed discovery and optimization and a final candidate is being selected for IND-enabling steps.
RSS
